UNSPSC 51122404: Niacin/pentaerythritol tetranitrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV250. This VA Drug Class (CV250) classifies this compound as belonging to the group ANTIANGINALS.

UNSPSC 51122404 Niacin/pentaerythritol tetranitrate, a Commodity code, nominally covers specialized pharmaceutical compounds, but recent state and local solicitations under this code actually span a much broader pharmaceutical procurement landscape—advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs. State and local governments are using this code to solicit emergency medical supplies, wholesale pharmaceutical distribution agreements, and pharmacy benefit program infrastructure rather than the specific compound indicated by the code name alone. Soliciting bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple state and local members. The scope of work reflects active procurement for time-sensitive emergency medications with strict expiration-date and shelf-life requirements, standardized pharmaceutical sourcing through authorized wholesalers, and pilot initiatives to restructure pharmacy benefit delivery outside traditional pharmacy benefit manager and group purchasing organization channels.

Geographic activity spans Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving as a repeat buyer coordinating demand across multiple states including Oregon. Representative recent opportunities include the City of Tampa's sealed-bid IFB for Advanced Life Support Medications (Solicitation 26P00188, response due April 8, 2026, estimated contract value $40,000), which required four specific life-support drug line items with nine-month-minimum expiration dates, firm pricing including freight, and a 5 percent Small Local Business Enterprise bid discount; the Minnesota Department of Administration's MMCAP RFP for Generic Multi-Source Pharmaceuticals and OTC Products (S1070000015802, response due March 26, 2026), which established multi-award contracts with three authorized wholesalers effective July 1, 2026, emphasizing price competitiveness (75 percent of evaluation weight) and compliance with cGMP and Drug Supply Chain Security Act requirements; and the Texas Health and Human Services Commission's RFI on Direct-to-Manufacturer Prescriptions (HHS0017013, posted April 3, 2026), which explores vendor capacity for bypassing traditional PBM and GPO channels to negotiate net pricing with manufacturers for state self-insured employee and retiree plans.